{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T09:17:14Z","timestamp":1787995034215,"version":"build-2784847793"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s10067-026-08285-7","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T02:17:24Z","timestamp":1784081844000},"page":"5201-5214","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gout: a practical approach to diagnosis and management in low- and middle-income countries and resource-limited settings"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1956-7651","authenticated-orcid":false,"given":"Patapong","family":"Towiwat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9846-1491","authenticated-orcid":false,"given":"Suppachai","family":"Lawanaskol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3105-6122","authenticated-orcid":false,"given":"Worawit","family":"Louthrenoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"issue":"20","key":"8285_CR1","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1056\/NEJMcp2203385","volume":"387","author":"TR Mikuls","year":"2022","unstructured":"Mikuls TR (2022) Gout. N Engl J Med 387(20):1877\u20131887. https:\/\/doi.org\/10.1056\/NEJMcp2203385","journal-title":"N Engl J Med"},{"issue":"5","key":"8285_CR2","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3899\/jrheum.090034","volume":"36","author":"SY Kim","year":"2009","unstructured":"Kim SY, Choi HK (2009) Gout and quality of life. J Rheumatol 36(5):865\u2013868. https:\/\/doi.org\/10.3899\/jrheum.090034","journal-title":"J Rheumatol"},{"key":"8285_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2023.152273","volume":"63","author":"X Wang","year":"2023","unstructured":"Wang X, Li X, Wang H, Chen M, Wen C, Huang L et al (2023) All-cause and specific mortality in patients with gout: a systematic review and meta-analysis. Semin Arthritis Rheum 63:152273. https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152273","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"8285_CR4","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1136\/annrheumdis-2015-208237","volume":"74","author":"T Neogi","year":"2015","unstructured":"Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D et al (2015) 2015 Gout classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 74(10):1789\u20131798. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208237","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"8285_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1136\/annrheumdis-2019-215315","volume":"79","author":"P Richette","year":"2020","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda J et al (2020) 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Ann Rheum Dis 79(1):31\u201338. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215315","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"8285_CR6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/1756-185x.14266","volume":"25","author":"JPP Lorenzo","year":"2022","unstructured":"Lorenzo JPP, Sollano M, Salido EO, Li-Yu J, Tankeh-Torres SA, Wulansari Manuaba IAR et al (2022) 2021 Asia-Pacific League of Associations for Rheumatology clinical practice guideline for treatment of gout. Int J Rheum Dis 25(1):7\u201320. https:\/\/doi.org\/10.1111\/1756-185x.14266","journal-title":"Int J Rheum Dis"},{"issue":"3","key":"8285_CR7","doi-asserted-by":"publisher","first-page":"141","DOI":"10.4078\/jrd.2023.0029","volume":"30","author":"JJ Lee","year":"2023","unstructured":"Lee JJ, Lee JS, Chung MK, Ahn JK, Choi HJ, Hong SJ et al (2023) Korean guidelines for the management of gout. J Rheum Dis 30(3):141\u2013150. https:\/\/doi.org\/10.4078\/jrd.2023.0029","journal-title":"J Rheum Dis"},{"issue":"8","key":"8285_CR8","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1007\/s10067-023-06578-9","volume":"42","author":"RM Yip","year":"2023","unstructured":"Yip RM, Cheung TT, So H, Chan JP, Ho CT, Tsang HH et al (2023) The Hong Kong Society of Rheumatology consensus recommendations for the management of gout. Clin Rheumatol 42(8):2013\u20132027. https:\/\/doi.org\/10.1007\/s10067-023-06578-9","journal-title":"Clin Rheumatol"},{"issue":"7","key":"8285_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185x.70375","volume":"28","author":"M Sun","year":"2025","unstructured":"Sun M, Lyu Z, Wang C, Li Y, Zhao D, Ran X et al (2025) 2024 update of Chinese guidelines for diagnosis and treatment of hyperuricemia and gout part I: recommendations for general patients. Int J Rheum Dis 28(7):e70375. https:\/\/doi.org\/10.1111\/1756-185x.70375","journal-title":"Int J Rheum Dis"},{"issue":"2","key":"8285_CR10","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1136\/annrheumdis-2013-203325","volume":"73","author":"F Sivera","year":"2014","unstructured":"Sivera F, Andr\u00e9s M, Carmona L, Kydd AS, Moi J, Seth R et al (2014) Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis 73(2):328\u2013335. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203325","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"8285_CR11","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/1756-185x.12557","volume":"18","author":"SW Graf","year":"2015","unstructured":"Graf SW, Whittle SL, Wechalekar MD, Moi JH, Barrett C, Hill CL et al (2015) Australian and New Zealand recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion in the 3e Initiative. Int J Rheum Dis 18(3):341\u2013351. https:\/\/doi.org\/10.1111\/1756-185x.12557","journal-title":"Int J Rheum Dis"},{"issue":"6","key":"8285_CR12","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/acr.24180","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T, Brignardello PR, Guyatt G et al (2020) 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res 72(6):744\u2013760. https:\/\/doi.org\/10.1002\/acr.24180","journal-title":"Arthritis Care Res"},{"issue":"1","key":"8285_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda-Sanabria J et al (2017) 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 76(1):29\u201342. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209707","journal-title":"Ann Rheum Dis"},{"issue":"suppl_1","key":"8285_CR14","doi-asserted-by":"publisher","first-page":"i20","DOI":"10.1093\/rheumatology\/kex442","volume":"57","author":"F Perez-Ruiz","year":"2018","unstructured":"Perez-Ruiz F, Moreno-Lledo A, Urionaguena I, Dickson AJ (2018) Treat to target in gout. Rheumatology (Oxford) 57(suppl_1):i20\u2013i26. https:\/\/doi.org\/10.1093\/rheumatology\/kex442","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"8285_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2025.105892","volume":"92","author":"T Pascart","year":"2025","unstructured":"Pascart T, Richette P, Bousson V, Ottaviani S, Ea HK, Liote F et al (2025) Time-course of tophus resolution on Dual-energy CT and ultrasound after 24 months of a treat-to-target strategy: results from GOUT-DECTUS study. Joint Bone Spine 92(4):105892. https:\/\/doi.org\/10.1016\/j.jbspin.2025.105892","journal-title":"Joint Bone Spine"},{"issue":"1","key":"8285_CR16","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ard.2025.05.017","volume":"85","author":"AD Tabi-Amponsah","year":"2026","unstructured":"Tabi-Amponsah AD, Stewart S, Stamp LK, Taylor WJ, Terkeltaub R, Dalbeth N (2026) The Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) definition of clinical remission in gout. Ann Rheum Dis 85(1):186\u2013194. https:\/\/doi.org\/10.1016\/j.ard.2025.05.017","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"8285_CR17","doi-asserted-by":"publisher","first-page":"e507","DOI":"10.1016\/S2665-9913(24)00117-6","volume":"6","author":"Global Burden of Disease Gout","year":"2021","unstructured":"Global Burden of Disease Gout (2021) Collaborators (2024) Global, regional, and national burden of gout, 1990\u20132020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol 6(8):e507\u2013e517. https:\/\/doi.org\/10.1016\/S2665-9913(24)00117-6","journal-title":"Lancet Rheumatol"},{"issue":"2","key":"8285_CR18","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.idc.2017.01.001","volume":"31","author":"JJ Ross","year":"2017","unstructured":"Ross JJ (2017) Septic arthritis of native joints. Infect Dis Clin North Am 31(2):203\u2013218. https:\/\/doi.org\/10.1016\/j.idc.2017.01.001","journal-title":"Infect Dis Clin North Am"},{"issue":"3","key":"8285_CR19","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.idc.2025.05.001","volume":"39","author":"B Estipona","year":"2025","unstructured":"Estipona B, Collins GL, Sivapalan S, Montgomery S, Riaz T (2025) Native joint septic arthritis. Infect Dis Clin North Am 39(3):449\u2013463. https:\/\/doi.org\/10.1016\/j.idc.2025.05.001","journal-title":"Infect Dis Clin North Am"},{"issue":"11","key":"8285_CR20","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1093\/rheumatology\/kev236","volume":"54","author":"SY Lim","year":"2015","unstructured":"Lim SY, Lu N, Choi HK (2015) Septic arthritis in gout patients: a population-based cohort study. Rheumatology (Oxford) 54(11):2095\u20132099. https:\/\/doi.org\/10.1093\/rheumatology\/kev236","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"8285_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12873-020-00319-w","volume":"20","author":"P Towiwat","year":"2020","unstructured":"Towiwat P, Phungoen P, Tantrawiwat K, Laohakul P, Aiewruengsurat D, Thanadetsuntorn C et al (2020) Quality of gout care in the emergency departments: a multicentre study. BMC Emerg Med 20(1):27. https:\/\/doi.org\/10.1186\/s12873-020-00319-w","journal-title":"BMC Emerg Med"},{"issue":"1","key":"8285_CR22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jemermed.2006.07.019","volume":"32","author":"K Shah","year":"2007","unstructured":"Shah K, Spear J, Nathanson LA, McCauley J, Edlow JA (2007) Does the presence of crystal arthritis rule out septic arthritis? J Emerg Med 32(1):23\u201326. https:\/\/doi.org\/10.1016\/j.jemermed.2006.07.019","journal-title":"J Emerg Med"},{"issue":"1","key":"8285_CR23","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3899\/jrheum.110368","volume":"39","author":"LE Papanicolas","year":"2012","unstructured":"Papanicolas LE, Hakendorf P, Gordon DL (2012) Concomitant septic arthritis in crystal monoarthritis. J Rheumatol 39(1):157\u2013160. https:\/\/doi.org\/10.3899\/jrheum.110368","journal-title":"J Rheumatol"},{"issue":"3","key":"8285_CR24","doi-asserted-by":"publisher","first-page":"118","DOI":"10.7150\/jbji.44815","volume":"5","author":"TD Luo","year":"2020","unstructured":"Luo TD, Jarvis DL, Yancey HB, Zuskov A, Tipton SC, Langfitt MK et al (2020) Synovial cell count poorly predicts septic arthritis in the presence of crystalline arthropathy. J Bone Jt Infect 5(3):118\u2013124. https:\/\/doi.org\/10.7150\/jbji.44815","journal-title":"J Bone Jt Infect"},{"issue":"3","key":"8285_CR25","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1515\/rir-2025-0021","volume":"6","author":"K Duangkum","year":"2025","unstructured":"Duangkum K, Saengmongkonpipat P, Tantiwong P, Siriphannon Y, Phungtaharn T (2025) Prevalence and characteristics of concomitant septic and crystal-induced arthritis: a hospital database and literature review. Rheumatol Immunol Res 6(3):179\u2013187. https:\/\/doi.org\/10.1515\/rir-2025-0021","journal-title":"Rheumatol Immunol Res"},{"issue":"9","key":"8285_CR26","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1093\/rheumatology\/keg297","volume":"42","author":"KH Yu","year":"2003","unstructured":"Yu KH, Luo SF, Liou LB, Wu YJ, Tsai WP, Chen JY et al (2003) Concomitant septic and gouty arthritis\u2013an analysis of 30 cases. Rheumatology (Oxford) 42(9):1062\u20131066. https:\/\/doi.org\/10.1093\/rheumatology\/keg297","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"8285_CR27","first-page":"902","volume":"27","author":"CT Weng","year":"2009","unstructured":"Weng CT, Liu MF, Lin LH, Weng MY, Lee NY, Wu AB et al (2009) Rare coexistence of gouty and septic arthritis: a report of 14 cases. Clin Exp Rheumatol 27(6):902\u2013906","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"8285_CR28","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.berh.2005.01.004","volume":"19","author":"E Pascual","year":"2005","unstructured":"Pascual E, Jovani V (2005) Synovial fluid analysis. Best Pract Res Clin Rheumatol 19(3):371\u2013386. https:\/\/doi.org\/10.1016\/j.berh.2005.01.004","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"2","key":"8285_CR29","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/BOR.0b013e328343e458","volume":"23","author":"E Pascual","year":"2011","unstructured":"Pascual E, Sivera F, Andres M (2011) Synovial fluid analysis for crystals. Curr Opin Rheumatol 23(2):161\u2013169. https:\/\/doi.org\/10.1097\/BOR.0b013e328343e458","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"8285_CR30","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s00296-017-3708-3","volume":"37","author":"W Louthrenoo","year":"2017","unstructured":"Louthrenoo W, Jatuworapruk K, Lhakum P, Pattamapaspong N (2017) Performance of the 2015 American College of Rheumatology\/European League Against Rheumatism gout classification criteria in Thai patients. Rheumatol Int 37(5):705\u2013711. https:\/\/doi.org\/10.1007\/s00296-017-3708-3","journal-title":"Rheumatol Int"},{"issue":"1","key":"8285_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2023.101848","volume":"37","author":"F Oliviero","year":"2023","unstructured":"Oliviero F, Mandell BF (2023) Synovial fluid analysis: relevance for daily clinical practice. Best Pract Res Clin Rheumatol 37(1):101848. https:\/\/doi.org\/10.1016\/j.berh.2023.101848","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"8285_CR32","volume-title":"Atlas of synovial fluid analysis and crystal identification","author":"HR Schumacher","year":"1991","unstructured":"Schumacher HR, Reginatio A (1991) Atlas of synovial fluid analysis and crystal identification. Lea&Febiger, Philadelphia"},{"issue":"12","key":"8285_CR33","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1136\/ard.48.12.983","volume":"48","author":"E Pascual","year":"1989","unstructured":"Pascual E, Tovar J, Ruiz MT (1989) The ordinary light microscope: an appropriate tool for provisional detection and identification of crystals in synovial fluid. Ann Rheum Dis 48(12):983\u2013985. https:\/\/doi.org\/10.1136\/ard.48.12.983","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"8285_CR34","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s10067-016-3461-0","volume":"36","author":"D Berendsen","year":"2017","unstructured":"Berendsen D, Neogi T, Taylor WJ, Dalbeth N, Jansen TL (2017) Crystal identification of synovial fluid aspiration by polarized light microscopy. An online test suggesting that our traditional rheumatologic competence needs renewed attention and training. Clin Rheumatol 36(3):641\u2013647. https:\/\/doi.org\/10.1007\/s10067-016-3461-0","journal-title":"Clin Rheumatol"},{"key":"8285_CR35","doi-asserted-by":"publisher","unstructured":"Wali L, Rowbotham E (2025) Imaging of gout: an atlas. Rheumatol Adv Pract 9(2):rkaf051. https:\/\/doi.org\/10.1093\/rap\/rkaf051","DOI":"10.1093\/rap\/rkaf051"},{"key":"8285_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2024.152470","volume":"68","author":"ML Peral-Garrido","year":"2024","unstructured":"Peral-Garrido ML, Gomez-Sabater S, Cano R, Bermudez-Garcia A, Lozano T, Sanchez-Ortiga R et al (2024) Prevalence of crystal deposits in asymptomatic hyperuricemia according to different scanning definitions: a comparative study. Semin Arthritis Rheum 68:152470. https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152470","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"8285_CR37","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14366\/usg.20063","volume":"40","author":"C Schwabl","year":"2021","unstructured":"Schwabl C, Taljanovic M, Widmann G, Teh J, Klauser AS (2021) Ultrasonography and dual-energy computed tomography: impact for the detection of gouty deposits. Ultrasonography 40(2):197\u2013206. https:\/\/doi.org\/10.14366\/usg.20063","journal-title":"Ultrasonography"},{"issue":"1","key":"8285_CR38","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/jmrs.223","volume":"64","author":"H Chou","year":"2017","unstructured":"Chou H, Chin TY, Peh WC (2017) Dual-energy CT in gout - a review of current concepts and applications. J Med Radiat Sci 64(1):41\u201351. https:\/\/doi.org\/10.1002\/jmrs.223","journal-title":"J Med Radiat Sci"},{"issue":"1","key":"8285_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.29273\/jmst.2021.5.1.1","volume":"5","author":"AL de Freitas Tavares","year":"2021","unstructured":"de Freitas Tavares AL, Ross IM, Pradal LA, Neves M, Jamilk BHT, Bertolini GRF (2021) The use of cryotherapy in the gout pain control: a systematic review. J Musculoskelet Sci Technol 5(1):1\u20135. https:\/\/doi.org\/10.29273\/jmst.2021.5.1.1","journal-title":"J Musculoskelet Sci Technol"},{"issue":"10287","key":"8285_CR40","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1016\/S0140-6736(21)00569-9","volume":"397","author":"N Dalbeth","year":"2021","unstructured":"Dalbeth N, Gosling AL, Gaffo A, Abhishek A (2021) Gout. Lancet 397(10287):1843\u20131855. https:\/\/doi.org\/10.1016\/S0140-6736(21)00569-9","journal-title":"Lancet"},{"issue":"2","key":"8285_CR41","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/art.20007","volume":"50","author":"BR Rubin","year":"2004","unstructured":"Rubin BR, Burton R, Navarra S, Antigua J, Londono J, Pryhuber KG et al (2004) Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum 50(2):598\u2013606. https:\/\/doi.org\/10.1002\/art.20007","journal-title":"Arthritis Rheum"},{"issue":"9","key":"8285_CR42","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.3899\/jrheum.110916","volume":"39","author":"HR Schumacher","year":"2012","unstructured":"Schumacher HR, Berger MF, Li-Yu J, Perez-Ruiz F, Burgos-Vargas R, Li C (2012) Efficacy and tolerability of celecoxib in the treatment of acute gouty arthritis: a randomized controlled trial. J Rheumatol 39(9):1859\u20131866. https:\/\/doi.org\/10.3899\/jrheum.110916","journal-title":"J Rheumatol"},{"issue":"4","key":"8285_CR43","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/art.27327","volume":"62","author":"RA Terkeltaub","year":"2010","unstructured":"Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW (2010) High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 62(4):1060\u20131068. https:\/\/doi.org\/10.1002\/art.27327","journal-title":"Arthritis Rheum"},{"issue":"12","key":"8285_CR44","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1111\/1756-185X.14943","volume":"26","author":"P Laosuksri","year":"2023","unstructured":"Laosuksri P, Phrintrakul N, Gumtorntip W, Na-Nan K, Wongthanee A, Kasitanon N et al (2023) Non-loading versus loading low-dose colchicine in acute crystal-associated arthritis: a double-blinded randomized controlled study. Int J Rheum Dis 26(12):2478\u20132488. https:\/\/doi.org\/10.1111\/1756-185X.14943","journal-title":"Int J Rheum Dis"},{"issue":"4","key":"8285_CR45","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1136\/annrheumdis-2016-209467","volume":"76","author":"U Kiltz","year":"2017","unstructured":"Kiltz U, Smolen J, Bardin T, Cohen Solal A, Dalbeth N, Doherty M et al (2017) Treat-to-target (T2T) recommendations for gout. Ann Rheum Dis 76(4):632\u2013638. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209467","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"8285_CR46","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1177\/1759720X16646703","volume":"8","author":"SE Sattui","year":"2016","unstructured":"Sattui SE, Gaffo AL (2016) Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications. Ther Adv Musculoskelet Dis 8(4):145\u2013159. https:\/\/doi.org\/10.1177\/1759720X16646703","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"1","key":"8285_CR47","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1136\/ard.2007.083071","volume":"68","author":"MK Reinders","year":"2009","unstructured":"Reinders MK, van Roon EN, Jansen TL, Delsing J, Griep EN, Hoekstra M et al (2009) Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis 68(1):51\u201356. https:\/\/doi.org\/10.1136\/ard.2007.083071","journal-title":"Ann Rheum Dis"},{"key":"8285_CR48","doi-asserted-by":"publisher","unstructured":"Mor AL, Kaminski TW, Karbowska M, Pawlak D (2018) New insight into organic anion transporters from the perspective of potentially important interactions and drugs toxicity. J Physiol Pharmacol 69(3). https:\/\/doi.org\/10.26402\/jpp.2018.3.01","DOI":"10.26402\/jpp.2018.3.01"},{"issue":"2","key":"8285_CR49","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/j.1552-4604.1996.tb04182.x","volume":"36","author":"H Shimodaira","year":"1996","unstructured":"Shimodaira H, Takahashi K, Kano K, Matsumoto Y, Uchida Y, Kudo T (1996) Enhancement of anticoagulant action by warfarin-benzbromarone interaction. J Clin Pharmacol 36(2):168\u2013174. https:\/\/doi.org\/10.1002\/j.1552-4604.1996.tb04182.x","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"8285_CR50","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1124\/dmd.105.005884","volume":"33","author":"DF McGinnity","year":"2005","unstructured":"McGinnity DF, Tucker J, Trigg S, Riley RJ (2005) Prediction of CYP2C9-mediated drug-drug interactions: a comparison using data from recombinant enzymes and human hepatocytes. Drug Metab Dispos 33(11):1700\u20131707. https:\/\/doi.org\/10.1124\/dmd.105.005884","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"8285_CR51","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1046\/j.1523-1755.2003.t01-2-00171.x","volume":"64","author":"HJ Kramer","year":"2003","unstructured":"Kramer HJ, Choi HK, Atkinson K, Stampfer M, Curhan GC (2003) The association between gout and nephrolithiasis in men: the Health Professionals\u2019 Follow-Up Study. Kidney Int 64(3):1022\u20131026. https:\/\/doi.org\/10.1046\/j.1523-1755.2003.t01-2-00171.x","journal-title":"Kidney Int"},{"issue":"6","key":"8285_CR52","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.7326\/0003-4819-67-6-1133","volume":"67","author":"T Yu","year":"1967","unstructured":"Yu T, Gutman AB (1967) Uric acid nephrolithiasis in gout. Predisposing factors. Ann Intern Med 67(6):1133\u20131148. https:\/\/doi.org\/10.7326\/0003-4819-67-6-1133","journal-title":"Ann Intern Med"},{"key":"8285_CR53","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf577","author":"C Dahanayake","year":"2026","unstructured":"Dahanayake C, Bajpai R, Lambie M, Jordan KM, Roddy E (2026) Incidence and risk of nephrolithiasis with uricosuric therapies for the treatment of gout: a systematic review and meta-analysis of randomized controlled trials and cohort studies. Rheumatology (Oxford). https:\/\/doi.org\/10.1093\/rheumatology\/keaf577","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"8285_CR54","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12894-020-00690-7","volume":"20","author":"B Minotti","year":"2020","unstructured":"Minotti B, Treglia G, Pascale M, Ceruti S, Cantini L, Anselmi L et al (2020) Prevalence of microhematuria in renal colic and urolithiasis: a systematic review and meta-analysis. BMC Urol 20(1):119. https:\/\/doi.org\/10.1186\/s12894-020-00690-7","journal-title":"BMC Urol"},{"issue":"13","key":"8285_CR55","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2020.35.e95","volume":"35","author":"ST Choi","year":"2020","unstructured":"Choi ST, Song JS, Kim SJ, Kim CH, Moon SJ (2020) The utility of the random urine uric acid-to-creatinine ratio for patients with gout who need uricosuric agents: retrospective cross-sectional study. J Korean Med Sci 35(13):e95. https:\/\/doi.org\/10.3346\/jkms.2020.35.e95","journal-title":"J Korean Med Sci"},{"key":"8285_CR56","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1159\/000082540","volume":"147","author":"F Pea","year":"2005","unstructured":"Pea F (2005) Pharmacology of drugs for hyperuricemia. Mechanisms, kinetics and interactions. Contrib Nephrol 147:35\u201346. https:\/\/doi.org\/10.1159\/000082540","journal-title":"Contrib Nephrol"},{"issue":"4","key":"8285_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2020.101501","volume":"34","author":"LK Stamp","year":"2020","unstructured":"Stamp LK, Chapman PT (2020) Allopurinol hypersensitivity: pathogenesis and prevention. Best Pract Res Clin Rheumatol 34(4):101501. https:\/\/doi.org\/10.1016\/j.berh.2020.101501","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"1","key":"8285_CR58","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/cpt.1944","volume":"109","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Krebs K, Milani L, Lauschke VM (2021) Global frequencies of clinically important HLA alleles and their implications for the cost-effectiveness of preemptive pharmacogenetic testing. Clin Pharmacol Ther 109(1):160\u2013174. https:\/\/doi.org\/10.1002\/cpt.1944","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"8285_CR59","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1111\/1756-185X.13143","volume":"20","author":"KH Yu","year":"2017","unstructured":"Yu KH, Yu CY, Fang YF (2017) Diagnostic utility of HLA-B*5801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta-analysis. Int J Rheum Dis 20(9):1057\u20131071. https:\/\/doi.org\/10.1111\/1756-185X.13143","journal-title":"Int J Rheum Dis"},{"issue":"12","key":"8285_CR60","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1001\/jamadermatol.2025.4240","volume":"161","author":"CN Campbell","year":"2025","unstructured":"Campbell CN, Krantz MS, Yu A, Phillips EJ, Stevens-Johnson Syndrome\/Toxic Epidermal Necrolysis Survivor Study Collaborators (2025) HLA-B*58:01 and risk of allopurinol-induced severe cutaneous adverse reactions in the US. JAMA Dermatol 161(12):1258\u20131263. https:\/\/doi.org\/10.1001\/jamadermatol.2025.4240","journal-title":"JAMA Dermatol"},{"issue":"9","key":"8285_CR61","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.2146\/ajhp160243","volume":"74","author":"X Li","year":"2017","unstructured":"Li X, Zhao Z, Sun SS (2017) Association of human leukocyte antigen variants and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a meta-analysis. Am J Health Syst Pharm 74(9):e183\u2013e192. https:\/\/doi.org\/10.2146\/ajhp160243","journal-title":"Am J Health Syst Pharm"},{"issue":"2","key":"8285_CR62","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/fpc.0000000000000319","volume":"28","author":"HY Chong","year":"2018","unstructured":"Chong HY, Lim YH, Prawjaeng J, Tassaneeyakul W, Mohamed Z, Chaiyakunapruk N (2018) Cost-effectiveness analysis of HLA-B*58: 01 genetic testing before initiation of allopurinol therapy to prevent allopurinol-induced Stevens-Johnson syndrome\/toxic epidermal necrolysis in a Malaysian population. Pharmacogenet Genomics 28(2):56\u201367. https:\/\/doi.org\/10.1097\/fpc.0000000000000319","journal-title":"Pharmacogenet Genomics"},{"issue":"8","key":"8285_CR63","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.70093","volume":"7","author":"P Dilokthornsakul","year":"2025","unstructured":"Dilokthornsakul P, Louthrenoo W, Yadee J, Siripaitoon B, Jatuworapruk K, Vannaprasaht S et al (2025) An updated economic evaluation of HLA-B*58:01 genotype testing in gouty patients for preventing severe allopurinol hypersensitivity in Thailand. ACR Open Rheumatol 7(8):e70093. https:\/\/doi.org\/10.1002\/acr2.70093","journal-title":"ACR Open Rheumatol"},{"issue":"16","key":"8285_CR64","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.2217\/pgs.15.125","volume":"16","author":"D Dong","year":"2015","unstructured":"Dong D, Tan-Koi WC, Teng GG, Finkelstein E, Sung C (2015) Cost-effectiveness analysis of genotyping for HLA-B*5801 and an enhanced safety program in gout patients starting allopurinol in Singapore. Pharmacogenomics 16(16):1781\u20131793. https:\/\/doi.org\/10.2217\/pgs.15.125","journal-title":"Pharmacogenomics"},{"issue":"13","key":"8285_CR65","doi-asserted-by":"publisher","first-page":"713","DOI":"10.2217\/pgs-2023-0095","volume":"24","author":"KN Duong","year":"2023","unstructured":"Duong KN, Nguyen DV, Chaiyakunapruk N, Nelson RE, Malone DC (2023) Cost-effectiveness of HLA-B*58:01 testing to prevent Stevens-Johnson syndrome\/toxic epidermal necrolysis in Vietnam. Pharmacogenomics 24(13):713\u2013724. https:\/\/doi.org\/10.2217\/pgs-2023-0095","journal-title":"Pharmacogenomics"},{"issue":"4","key":"8285_CR66","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2217\/pgs-2019-0160","volume":"21","author":"GG Teng","year":"2020","unstructured":"Teng GG, Tan-Koi WC, Dong D, Sung C (2020) Is HLA-B*58:01 genotyping cost effective in guiding allopurinol use in gout patients with chronic kidney disease? Pharmacogenomics 21(4):279\u2013291. https:\/\/doi.org\/10.2217\/pgs-2019-0160","journal-title":"Pharmacogenomics"},{"issue":"5","key":"8285_CR67","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/fpc.0000000000000334","volume":"28","author":"H Cheng","year":"2018","unstructured":"Cheng H, Yan D, Zuo X, Liu J, Liu W, Zhang Y (2018) A retrospective investigation of HLA-B*5801 in hyperuricemia patients in a Han population of China. Pharmacogenet Genomics 28(5):117\u2013124. https:\/\/doi.org\/10.1097\/fpc.0000000000000334","journal-title":"Pharmacogenet Genomics"},{"issue":"6","key":"8285_CR68","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3899\/jrheum.151476","volume":"44","author":"CH Ke","year":"2017","unstructured":"Ke CH, Chung WH, Wen YH, Huang YB, Chuang HY, Tain YL et al (2017) Cost-effectiveness analysis for genotyping before allopurinol treatment to prevent severe cutaneous adverse drug reactions. J Rheumatol 44(6):835\u2013843. https:\/\/doi.org\/10.3899\/jrheum.151476","journal-title":"J Rheumatol"},{"issue":"2","key":"8285_CR69","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/acr.22409","volume":"67","author":"DJ Park","year":"2015","unstructured":"Park DJ, Kang JH, Lee JW, Lee KE, Wen L, Kim TJ et al (2015) Cost-effectiveness analysis of HLA-B5801 genotyping in the treatment of gout patients with chronic renal insufficiency in Korea. Arthritis Care Res (Hoboken) 67(2):280\u2013287. https:\/\/doi.org\/10.1002\/acr.22409","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7","key":"8285_CR70","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s00403-021-02258-3","volume":"314","author":"CS Wong","year":"2022","unstructured":"Wong CS, Yeung CK, Chan CY, Yap DY, Tang SC, Cheung BM et al (2022) HLA-B*58:01 screening to prevent allopurinol-induced severe cutaneous adverse reactions in Chinese patients with chronic kidney disease. Arch Dermatol Res 314(7):651\u2013659. https:\/\/doi.org\/10.1007\/s00403-021-02258-3","journal-title":"Arch Dermatol Res"},{"key":"8285_CR71","doi-asserted-by":"publisher","unstructured":"Hande KR, Noone RM, Stone WJ (1984) Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 76(1):47\u201356. https:\/\/doi.org\/10.1016\/0002-9343(84)90743-5","DOI":"10.1016\/0002-9343(84)90743-5"},{"issue":"8","key":"8285_CR72","first-page":"1646","volume":"33","author":"N Dalbeth","year":"2006","unstructured":"Dalbeth N, Kumar S, Stamp L, Gow P (2006) Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 33(8):1646\u20131650","journal-title":"J Rheumatol"},{"issue":"e54","key":"8285_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1463423621000608","volume":"22","author":"M Liu","year":"2021","unstructured":"Liu M, Gao Z, Zhang H, Yuan X, Lu Y, Meng J (2021) General practitioners\u2019 knowledge of gout and its management: a case study in Beijing. Prim Health Care Res Dev 22(e54):1\u20138. https:\/\/doi.org\/10.1017\/S1463423621000608","journal-title":"Prim Health Care Res Dev"},{"issue":"1","key":"8285_CR74","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/00124743-199702000-00005","volume":"3","author":"MV Medellin","year":"1997","unstructured":"Medellin MV, Erickson AR, Enzenauer RJ (1997) Variability of treatment for gouty arthritis between rheumatologists and primary care physicians. J Clin Rheumatol 3(1):24\u201327. https:\/\/doi.org\/10.1097\/00124743-199702000-00005","journal-title":"J Clin Rheumatol"},{"issue":"12","key":"8285_CR75","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1007\/s10067-016-3423-6","volume":"35","author":"MA Ozturk","year":"2016","unstructured":"Ozturk MA, Mercan R, Gok K, Onat AM, Kisacik B, Kimyon G et al (2016) The management of gout in different clinical specialties in Turkey: a patient-based survey. Clin Rheumatol 35(12):3019\u20133024. https:\/\/doi.org\/10.1007\/s10067-016-3423-6","journal-title":"Clin Rheumatol"},{"issue":"1","key":"8285_CR76","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s10067-014-2783-z","volume":"34","author":"A Jeyaruban","year":"2015","unstructured":"Jeyaruban A, Larkins S, Soden M (2015) Management of gout in general practice\u2013a systematic review. Clin Rheumatol 34(1):9\u201316. https:\/\/doi.org\/10.1007\/s10067-014-2783-z","journal-title":"Clin Rheumatol"},{"issue":"6","key":"8285_CR77","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.3899\/jrheum.080938","volume":"36","author":"N Schlesinger","year":"2009","unstructured":"Schlesinger N, Norquist JM, Watson DJ (2009) Serum urate during acute gout. J Rheumatol 36(6):1287\u20131289. https:\/\/doi.org\/10.3899\/jrheum.080938","journal-title":"J Rheumatol"},{"issue":"10","key":"8285_CR78","doi-asserted-by":"publisher","first-page":"756","DOI":"10.7326\/0003-4819-131-10-199911160-00007","volume":"131","author":"E Pascual","year":"1999","unstructured":"Pascual E, Batlle-Gualda E, Mart\u00ednez A, Rosas J, Vela P (1999) Synovial fluid analysis for diagnosis of intercritical gout. Ann Intern Med 131(10):756\u2013759. https:\/\/doi.org\/10.7326\/0003-4819-131-10-199911160-00007","journal-title":"Ann Intern Med"},{"issue":"9","key":"8285_CR79","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1136\/ard.57.9.545","volume":"57","author":"F Perez-Ruiz","year":"1998","unstructured":"Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, Herrero-Beites A, Garcia-Erauskin G, Ruiz-Lucea E (1998) Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 57(9):545\u2013549. https:\/\/doi.org\/10.1136\/ard.57.9.545","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"8285_CR80","first-page":"S40","volume":"85","author":"P Hanvivadhanakul","year":"2002","unstructured":"Hanvivadhanakul P, Akkasilpa S, Deesomchok U (2002) Efficacy of benzbromarone compared to allopurinol in lowering serum uric acid level in hyperuricemic patients. J Med Assoc Thai 85(Suppl 1):S40-47","journal-title":"J Med Assoc Thai"},{"issue":"6","key":"8285_CR81","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1136\/ard.2008.091462","volume":"68","author":"MK Reinders","year":"2009","unstructured":"Reinders MK, Haagsma C, Jansen TL, van Roon EN, Delsing J, van de Laar MA et al (2009) A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300\u2013600 mg\/day versus benzbromarone 100\u2013200 mg\/day in patients with gout. Ann Rheum Dis 68(6):892\u2013897. https:\/\/doi.org\/10.1136\/ard.2008.091462","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"8285_CR82","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1177\/030006058100900615","volume":"9","author":"GW Schepers","year":"1981","unstructured":"Schepers GW (1981) Benzbromarone therapy in hyperuricaemia; comparison with allopurinol and probenecid. J Int Med Res 9(6):511\u2013515. https:\/\/doi.org\/10.1177\/030006058100900615","journal-title":"J Int Med Res"},{"issue":"6 Suppl","key":"8285_CR83","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1136\/ard.25.Suppl_6.623","volume":"25","author":"JT Scott","year":"1966","unstructured":"Scott JT (1966) Comparison of allopurinol and probenecid. Ann Rheum Dis 25(6 Suppl):623\u2013626. https:\/\/doi.org\/10.1136\/ard.25.Suppl_6.623","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"8285_CR84","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s10067-006-0528-3","volume":"26","author":"MK Reinders","year":"2007","unstructured":"Reinders MK, van Roon EN, Houtman PM, Brouwers JR, Jansen TL (2007) Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients. Clin Rheumatol 26(9):1459\u20131465. https:\/\/doi.org\/10.1007\/s10067-006-0528-3","journal-title":"Clin Rheumatol"},{"key":"8285_CR85","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/263720","volume":"2014","author":"VF Azevedo","year":"2014","unstructured":"Azevedo VF, Buiar PG, Giovanella LH, Severo CR, Carvalho M (2014) Allopurinol, benzbromarone, or a combination in treating patients with gout: analysis of a series of outpatients. Int J Rheumatol 2014:263720. https:\/\/doi.org\/10.1155\/2014\/263720","journal-title":"Int J Rheumatol"},{"issue":"8","key":"8285_CR86","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1002\/art.34488","volume":"64","author":"LK Stamp","year":"2012","unstructured":"Stamp LK, Taylor WJ, Jones PB, Dockerty JL, Drake J, Frampton C et al (2012) Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum 64(8):2529\u20132536. https:\/\/doi.org\/10.1002\/art.34488","journal-title":"Arthritis Rheum"},{"issue":"12","key":"8285_CR87","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1136\/ard-2023-224731","volume":"82","author":"L Stamp","year":"2023","unstructured":"Stamp L, Horne A, Mihov B, Drake J, Haslett J, Chapman PT et al (2023) Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial. Ann Rheum Dis 82(12):1626\u20131634. https:\/\/doi.org\/10.1136\/ard-2023-224731","journal-title":"Ann Rheum Dis"},{"key":"8285_CR88","doi-asserted-by":"publisher","DOI":"10.1093\/med\/9780198796619.001.0001","volume-title":"Prognosis research in healthcare: concepts, methods, and impact","author":"RD Riley","year":"2019","unstructured":"Riley RD, van der Windt D, Croft P, Moons KGM (2019) Prognosis research in healthcare: concepts, methods, and impact. Oxford University Press"},{"key":"8285_CR89","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-026-07967-6","author":"S Lawanaskol","year":"2026","unstructured":"Lawanaskol S, Tassaneeyakul W, Sukasem C, Saksit N, Konyoung P, Nakkam N et al (2026) Development of a non-genetic risk prediction model for allopurinol-induced severe cutaneous adverse drug reactions: a multicenter retrospective observational study. Clin Rheumatol. https:\/\/doi.org\/10.1007\/s10067-026-07967-6","journal-title":"Clin Rheumatol"},{"issue":"12","key":"8285_CR90","doi-asserted-by":"publisher","first-page":"e840","DOI":"10.1016\/S2665-9913(25)00165-1","volume":"7","author":"E Cipolletta","year":"2025","unstructured":"Cipolletta E, Nakafero G, Rozza D, Mahil SK, Smith CH, Riley RD et al (2025) Development and validation of a prognostic model for predicting the risk of allopurinol-induced severe cutaneous adverse reactions: a retrospective new-user cohort study using linked primary care, hospitalisation, and mortality data. Lancet Rheumatol 7(12):e840\u2013e850. https:\/\/doi.org\/10.1016\/S2665-9913(25)00165-1","journal-title":"Lancet Rheumatol"},{"key":"8285_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2025.111902","volume":"186","author":"B Arshi","year":"2025","unstructured":"Arshi B, Cowley LE, Rijnhart E, Reeve K, Smits LJ, Wynants L (2025) External validation, impact assessment and clinical utilization of clinical prediction models: a prospective cohort study. J Clin Epidemiol 186:111902. https:\/\/doi.org\/10.1016\/j.jclinepi.2025.111902","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"8285_CR92","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.jid.2016.02.808","volume":"136","author":"CY Ng","year":"2016","unstructured":"Ng CY, Yeh YT, Wang CW, Hung SI, Yang CH, Chang YC et al (2016) Impact of the HLA-B(*)58:01 allele and renal impairment on allopurinol-induced cutaneous adverse reactions. J Invest Dermatol 136(7):1373\u20131381. https:\/\/doi.org\/10.1016\/j.jid.2016.02.808","journal-title":"J Invest Dermatol"},{"issue":"6033","key":"8285_CR93","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1136\/bmj.2.6033.458","volume":"2","author":"A Meyrier","year":"1976","unstructured":"Meyrier A (1976) Desensitisation in a patient with chronic renal disease and severe allergy to allopurinol. Br Med J 2(6033):458. https:\/\/doi.org\/10.1136\/bmj.2.6033.458","journal-title":"Br Med J"},{"issue":"3","key":"8285_CR94","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/0002-9343(92)90236-5","volume":"93","author":"AG Fam","year":"1992","unstructured":"Fam AG, Lewtas J, Stein J, Paton TW (1992) Desensitization to allopurinol in patients with gout and cutaneous reactions. Am J Med 93(3):299\u2013302. https:\/\/doi.org\/10.1016\/0002-9343(92)90236-5","journal-title":"Am J Med"},{"issue":"5","key":"8285_CR95","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/00124743-200010000-00006","volume":"6","author":"J V\u00e1zquez-Mellado","year":"2000","unstructured":"V\u00e1zquez-Mellado J, V\u00e1zquez SG, Barrientos JC, R\u00edos VG, Burgos-Vargas R (2000) Desensitization to allopurinol after allopurinol hypersensitivity syndrome with renal involvement in gout. J Clin Rheumatol 6(5):266\u2013268. https:\/\/doi.org\/10.1097\/00124743-200010000-00006","journal-title":"J Clin Rheumatol"},{"issue":"1","key":"8285_CR96","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/1529-0131(200101)44:1<231::Aid-anr30>3.0.Co;2-7","volume":"44","author":"AG Fam","year":"2001","unstructured":"Fam AG, Dunne SM, Iazzetta J, Paton TW (2001) Efficacy and safety of desensitization to allopurinol following cutaneous reactions. Arthritis Rheum 44(1):231\u2013238. https:\/\/doi.org\/10.1002\/1529-0131(200101)44:1%3c231::Aid-anr30%3e3.0.Co;2-7","journal-title":"Arthritis Rheum"},{"issue":"10156","key":"8285_CR97","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S0140-6736(18)32158-5","volume":"392","author":"M Doherty","year":"2018","unstructured":"Doherty M, Jenkins W, Richardson H, Sarmanova A, Abhishek A, Ashton D et al (2018) Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. Lancet 392(10156):1403\u20131412. https:\/\/doi.org\/10.1016\/S0140-6736(18)32158-5","journal-title":"Lancet"},{"issue":"1","key":"8285_CR98","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s41927-022-00259-x","volume":"6","author":"ER Dorris","year":"2022","unstructured":"Dorris ER, Kieran M, Dalbeth N, McCarthy G (2022) Pharmacist knowledge of gout management: impact of an educational intervention. BMC Rheumatol 6(1):30. https:\/\/doi.org\/10.1186\/s41927-022-00259-x","journal-title":"BMC Rheumatol"},{"issue":"10","key":"8285_CR99","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1093\/heapol\/czy094","volume":"33","author":"M Woldie","year":"2018","unstructured":"Woldie M, Feyissa GT, Admasu B, Hassen K, Mitchell K, Mayhew S et al (2018) Community health volunteers could help improve access to and use of essential health services by communities in LMICs: an umbrella review. Health Policy Plan 33(10):1128\u20131143. https:\/\/doi.org\/10.1093\/heapol\/czy094","journal-title":"Health Policy Plan"},{"issue":"3","key":"8285_CR100","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1370\/afm.2208","volume":"16","author":"AL Hartzler","year":"2018","unstructured":"Hartzler AL, Tuzzio L, Hsu C, Wagner EH (2018) Roles and functions of community health workers in primary care. Ann Fam Med 16(3):240\u2013245. https:\/\/doi.org\/10.1370\/afm.2208","journal-title":"Ann Fam Med"},{"issue":"7","key":"8285_CR101","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1093\/rheumatology\/kex530","volume":"57","author":"SK Rai","year":"2018","unstructured":"Rai SK, Choi HK, Choi SHJ, Townsend AF, Shojania K, De Vera MA (2018) Key barriers to gout care: a systematic review and thematic synthesis of qualitative studies. Rheumatology (Oxford) 57(7):1282\u20131292. https:\/\/doi.org\/10.1093\/rheumatology\/kex530","journal-title":"Rheumatology (Oxford)"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08285-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08285-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08285-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T08:34:37Z","timestamp":1787992477000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08285-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":101,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["8285"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08285-7","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"25 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Institutional review board","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":3,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}